992 related articles for article (PubMed ID: 33412089)
1. COVID-19-neutralizing antibodies predict disease severity and survival.
Garcia-Beltran WF; Lam EC; Astudillo MG; Yang D; Miller TE; Feldman J; Hauser BM; Caradonna TM; Clayton KL; Nitido AD; Murali MR; Alter G; Charles RC; Dighe A; Branda JA; Lennerz JK; Lingwood D; Schmidt AG; Iafrate AJ; Balazs AB
Cell; 2021 Jan; 184(2):476-488.e11. PubMed ID: 33412089
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 neutralizing antibodies predict disease severity and survival.
Garcia-Beltran WF; Lam EC; Astudillo MG; Yang D; Miller TE; Feldman J; Hauser BM; Caradonna TM; Clayton KL; Nitido AD; Murali MR; Alter G; Charles RC; Dighe A; Branda JA; Lennerz JK; Lingwood D; Schmidt AG; Iafrate AJ; Balazs AB
medRxiv; 2020 Oct; ():. PubMed ID: 33106822
[TBL] [Abstract][Full Text] [Related]
3. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.
Peterhoff D; Glück V; Vogel M; Schuster P; Schütz A; Neubert P; Albert V; Frisch S; Kiessling M; Pervan P; Werner M; Ritter N; Babl L; Deichner M; Hanses F; Lubnow M; Müller T; Lunz D; Hitzenbichler F; Audebert F; Hähnel V; Offner R; Müller M; Schmid S; Burkhardt R; Glück T; Koller M; Niller HH; Graf B; Salzberger B; Wenzel JJ; Jantsch J; Gessner A; Schmidt B; Wagner R
Infection; 2021 Feb; 49(1):75-82. PubMed ID: 32827125
[TBL] [Abstract][Full Text] [Related]
4. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.
Iyer AS; Jones FK; Nodoushani A; Kelly M; Becker M; Slater D; Mills R; Teng E; Kamruzzaman M; Garcia-Beltran WF; Astudillo M; Yang D; Miller TE; Oliver E; Fischinger S; Atyeo C; Iafrate AJ; Calderwood SB; Lauer SA; Yu J; Li Z; Feldman J; Hauser BM; Caradonna TM; Branda JA; Turbett SE; LaRocque RC; Mellon G; Barouch DH; Schmidt AG; Azman AS; Alter G; Ryan ET; Harris JB; Charles RC
Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033172
[TBL] [Abstract][Full Text] [Related]
5. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.
Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G
Front Immunol; 2022; 13():830710. PubMed ID: 35173741
[TBL] [Abstract][Full Text] [Related]
7. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
[TBL] [Abstract][Full Text] [Related]
9. Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan.
Takeshita M; Nishina N; Moriyama S; Takahashi Y; Uwamino Y; Nagata M; Aoki W; Masaki K; Ishii M; Saya H; Kondo Y; Kaneko Y; Suzuki K; Fukunaga K; Takeuchi T;
Virology; 2021 Mar; 555():35-43. PubMed ID: 33450669
[TBL] [Abstract][Full Text] [Related]
10. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
Front Immunol; 2021; 12():723585. PubMed ID: 34489974
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
Front Immunol; 2021; 12():614436. PubMed ID: 33790892
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study.
Schlesinger T; Weißbrich B; Wedekink F; Notz Q; Herrmann J; Krone M; Sitter M; Schmid B; Kredel M; Stumpner J; Dölken L; Wischhusen J; Kranke P; Meybohm P; Lotz C
PLoS One; 2020; 15(11):e0242917. PubMed ID: 33232382
[TBL] [Abstract][Full Text] [Related]
13. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
[TBL] [Abstract][Full Text] [Related]
14. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
15. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
[TBL] [Abstract][Full Text] [Related]
16. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
[TBL] [Abstract][Full Text] [Related]
17. Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19.
Harrington WE; Trakhimets O; Andrade DV; Dambrauskas N; Raappana A; Jiang Y; Houck J; Selman W; Yang A; Vigdorovich V; Yeung W; Haglund M; Wallner J; Oldroyd A; Hardy S; Stewart SWA; Gervassi A; Van Voorhis W; Frenkel L; Sather DN
Cell Rep Med; 2021 Apr; 2(4):100253. PubMed ID: 33842901
[TBL] [Abstract][Full Text] [Related]
18. Stereotypic neutralizing V
Kim SI; Noh J; Kim S; Choi Y; Yoo DK; Lee Y; Lee H; Jung J; Kang CK; Song KH; Choe PG; Kim HB; Kim ES; Kim NJ; Seong MW; Park WB; Oh MD; Kwon S; Chung J
Sci Transl Med; 2021 Jan; 13(578):. PubMed ID: 33397677
[TBL] [Abstract][Full Text] [Related]
19. Evolution of antibody immunity to SARS-CoV-2.
Gaebler C; Wang Z; Lorenzi JCC; Muecksch F; Finkin S; Tokuyama M; Cho A; Jankovic M; Schaefer-Babajew D; Oliveira TY; Cipolla M; Viant C; Barnes CO; Bram Y; Breton G; Hägglöf T; Mendoza P; Hurley A; Turroja M; Gordon K; Millard KG; Ramos V; Schmidt F; Weisblum Y; Jha D; Tankelevich M; Martinez-Delgado G; Yee J; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Robbiani DF; Zhao Z; Gazumyan A; Schwartz RE; Hatziioannou T; Bjorkman PJ; Mehandru S; Bieniasz PD; Caskey M; Nussenzweig MC
Nature; 2021 Mar; 591(7851):639-644. PubMed ID: 33461210
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.
Rathe JA; Hemann EA; Eggenberger J; Li Z; Knoll ML; Stokes C; Hsiang TY; Netland J; Takehara KK; Pepper M; Gale M
J Infect Dis; 2021 Apr; 223(7):1120-1131. PubMed ID: 33367830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]